Recent randomised trials2,3 and Screening Trials4 showed that PSA testing results in reduced PCa-mortality but also leads to over-diagnosis emphasising the need to revise PSA-based screening for PCa to an individualised, risk stratified and informed decision-making model for men, especially at a younger age. This evidence concerns the gene PROS1 and posterior cortical atrophy.